The earnings call highlighted significant achievements, including the approval and launch of Sephience in major markets and a strong financial position. However, challenges were noted with Translarna and Emflaza revenues. Overall, the sentiment was positive, with promising growth prospects for Sephience.

Company Guidance -

Q3 2025

During the second quarter of 2025, PTC Therapeutics reported strong financial performance and strategic advancements. The company achieved total revenue of $179 million, driven by $118 million in revenue from marketed products and $96 million from the global DMD franchise. Notably, PTC highlighted the approval and anticipated success of Sephience for PKU, which is expected to exceed $1 billion in U.S. revenue. The European launch began in Germany in mid-July, with U.S. commercial distribution planned within two weeks. PTC also announced a strategic agreement to purchase an 8% to 12% net sales payment obligation related to Sephience for $225 million upfront. Financially, the company closed the quarter with approximately $1.99 billion in cash, supporting its commercial and R&D initiatives without requiring additional capital. Operational expenses included non-GAAP R&D expenses of $104 million and non-GAAP SG&A expenses of $76 million.

Sephience Approvals in the EU and US

Sephience received approval in the EU in late June and the US with broad labeling for patients aged 1 month and above, marking a significant milestone for PTC Therapeutics.

Strong Financial Position

PTC closed the quarter with approximately $1.99 billion in cash, supporting commercial and R&D initiatives without needing additional capital.

Solid Revenue Performance

Total revenue for the second quarter was $179 million, with $96 million from the global DMD franchise and $58 million in royalty revenue from Evrysdi.

Strategic Acquisition for Sephience

PTC acquired the annual global net sales payment obligation for Sephience from Censa Pharmaceuticals, viewed as a constructive use of cash reserves.

Positive Feedback for Sephience Launch

Initial feedback from healthcare providers worldwide has been highly positive, with active engagement in the US and European markets.

PTC Therapeutics (PTCT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PTCT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 23, 2025	2025 (Q3)	-1.02 / -	-1.39	―	―	―
Aug 07, 2025	2025 (Q2)	-1.02 / -0.83	-1.29	35.66% (+0.46)	―
May 06, 2025	2025 (Q1)	-1.01 / 10.04	-1.2	936.67% (+11.24)	―
Feb 27, 2025	2024 (Q4)	-0.54 / -0.85	-2.06	58.74% (+1.21)	―
Nov 07, 2024	2024 (Q3)	-1.52 / -1.39	-1.76	21.02% (+0.37)	―
Aug 08, 2024	2024 (Q2)	-1.12 / -1.29	-2.66	51.50% (+1.37)	―
Apr 25, 2024	2024 (Q1)	-1.27 / -1.20	-1.88	36.17% (+0.68)	―
Feb 29, 2024	2023 (Q4)	-0.14 / -2.06	-2.35	12.34% (+0.29)	―
Oct 26, 2023	2023 (Q3)	-1.06 / -1.76	-1.53	-15.03% (-0.23)	―
Aug 03, 2023	2023 (Q2)	-1.62 / -2.66	-2.13	-24.88% (-0.53)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PTCT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$50.36	$45.38	-9.89%
May 06, 2025	$36.19	$40.76	+12.63%
Feb 27, 2025	$50.57	$55.26	+9.27%
Nov 07, 2024	$42.96	$44.28	+3.07%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does PTC Therapeutics (PTCT) report earnings?

PTC Therapeutics (PTCT) is schdueled to report earning on Oct 23, 2025, After Close (Confirmed).

What is PTC Therapeutics (PTCT) earnings time?

PTC Therapeutics (PTCT) earnings time is at Oct 23, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is PTCT EPS forecast?

PTCT EPS forecast for the fiscal quarter 2025 (Q3) is -1.02.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing